Akero Therapeutics (NASDAQ:AKRO) Director Seth Loring Harrison bought 900,000 shares of the business’s stock in a transaction on Monday, June 24th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $14,400,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of AKRO traded down $0.91 during mid-day trading on Thursday, reaching $20.64. 71,758 shares of the company’s stock traded hands, compared to its average volume of 121,568. Akero Therapeutics has a 12 month low of $16.06 and a 12 month high of $21.94.
A number of equities research analysts have recently weighed in on AKRO shares. Evercore ISI started coverage on Akero Therapeutics in a report on Monday. They set an “outperform” rating and a $35.00 price target on the stock. JPMorgan Chase & Co. reaffirmed a “sell” rating and set a $18.00 price target on shares of ABB in a report on Monday. Roth Capital reaffirmed a “buy” rating on shares of Coeur Mining in a report on Monday. Finally, Jefferies Financial Group set a $189.00 price target on salesforce.com and gave the company a “buy” rating in a report on Monday.
Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.
Featured Article: What is the Quick Ratio?
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.